News
VTRS
17.76
-0.34%
-0.06
What Viatris (VTRS)'s FDA Approval of Weekly Gwyn Lo Contraceptive Patch Means For Shareholders
Simply Wall St · 14h ago
Viatris gains approval of Gwyn Lo contraceptive patch
Seeking Alpha · 1d ago
Viatris receives FDA approval for Gwyn Lo contraceptive patch
TipRanks · 1d ago
Viatris Secures FDA Approval For Gwyn Lo Contraceptive Patch
NASDAQ · 1d ago
VIATRIS - EXPECTS GWYN LO TO BE AVAILABLE LATER THIS YEAR
Reuters · 1d ago
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
PR Newswire · 1d ago
18 Ideal 'Safer' Buyable July Dogs Emerge After 10 Years Of Digging
Seeking Alpha · 1d ago
J.P. Morgan Sticks to Its Hold Rating for Viatris (VTRS)
TipRanks · 2d ago
Most S&P 500 stocks trade above 50-day moving average for first time since February
Seeking Alpha · 2d ago
These large-cap stocks combine A-rated profitability with low forward P/E ratios
Seeking Alpha · 3d ago
Weekly Report: what happened at VTRS last week (0720-0724)?
Weekly Report · 3d ago
Merck signs licensing deals with companies including Viatris for new HIV pill
Seeking Alpha · 6d ago
Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host Disease
Benzinga · 6d ago
EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR RUXOLITINIB VIATRIS
Reuters · 6d ago
Stock index futures edge higher as investors seek rebound after Thursday selloff
Seeking Alpha · 6d ago
Viatris’ Quarterly Earnings Preview: What You Need to Know
Barchart · 07/22 05:45
Trump outlines plans for up to 200% tariffs on generic drug imports starting in 2028
Seeking Alpha · 07/22 04:41
UBS Reaffirms Their Buy Rating on Viatris (VTRS)
TipRanks · 07/21 22:21
Weekly Report: what happened at VTRS last week (0713-0717)?
Weekly Report · 07/20 09:36
3 Unpopular Stocks We’re Skeptical Of
Barchart · 07/20 04:18
More
Webull provides a variety of real-time VTRS stock news. You can receive the latest news about Viatris Inc Ord Shs through multiple platforms. This information may help you make smarter investment decisions.
About VTRS
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.